Vital

Free tools

GLP-1 medication level chart

A GLP-1 medication level chart shows how much of a weekly dose is estimated to stay in the body over time. Semaglutide has a half-life of about 7 days and tirzepatide about 5 days, per their FDA labels. On a steady weekly dose, the level rises for about 4 to 5 half-lives and then stays near the same range.

mg
days

7 is weekly.

weeks

Up to 52.

The dose number to skip, for example 4 for the fourth dose.

01230123456789101112WeeksRelative level (mg-equivalent)Steady-state peakOne dose is 1 mg.

An estimate from published half-life, not a blood level. Not for dosing decisions.

Half-life
7 days
From the FDA label
Near steady state
28–35 days
About 4 to 5 half-lives, or 4–5 weeks
Steady-state peak
2× one dose
About 2 mg-equivalent
Week 12
50%
Of the steady-state peak, just before the next dose

Not medical advice. This tool does math on the numbers you enter. It does not know your medication, your vial, or your health. Confirm every dose and draw with your prescriber or pharmacist.

Worked example

Take semaglutide at the same dose every 7 days. The half-life is about 7 days.

  1. After one week, half of the first dose is left. The second dose brings the level to 1.5 doses.
  2. After two weeks, the level is 0.75 before the third dose and 1.75 after it.
  3. Each week adds less. The peak gets close to 2 doses, and the low point before a dose gets close to 1 dose.

Tirzepatide has a shorter half-life of about 5 days. On a weekly dose, its peak gets close to about 1.6 doses, and it reaches that range a little sooner.

How the math works

The chart uses first-order decay. After each half-life, half of the medication is left. The amount left from one dose after t days is the dose × 0.5^(t ÷ half-life).

The chart adds up what is left from every earlier dose at each point in time. This is called superposition. The steady-state peak is one dose ÷ (1 − 0.5^(interval ÷ half-life)).

The model treats each dose as fully absorbed at the time of the shot. A real shot under the skin absorbs over one to three days, so real peaks come later and are lower. Treat the chart as a shape, not a measurement. It is an estimate from published half-life, not a blood level, and not for dosing decisions.

Frequently asked questions

  • The FDA label for semaglutide (Wegovy) gives an elimination half-life of about 1 week. The FDA label for tirzepatide (Zepbound) gives a half-life of about 5 days. Retatrutide is investigational. Its phase 2 trial reported a half-life of about 6 days.

  • A medication gets close to steady state after about 4 to 5 half-lives on the same dose. That is about 4 to 5 weeks for semaglutide and about 3 to 4 weeks for tirzepatide. Each dose increase starts that process again.

  • No. It is an estimate from the published half-life with a simple model. Absorption, body weight, and other factors change real levels from person to person. Do not use it to decide when or how much to take.

  • With a missed dose, the level keeps falling for a full extra interval before the next dose. On a long half-life, the drop is gradual. The labels give specific rules for a missed dose, so ask your prescriber or pharmacist what to do.

  • Each weekly dose adds to what is left from the earlier doses. Because the half-life is close to a week, part of each dose is still there when the next one goes in. The total rises until the amount that leaves each week equals one dose.

Do this math automatically in Vital

Vital estimates how much of your last logged dose is still in your system, from its half-life. It also reminds you when each dose is due.

Sources

  1. Wegovy® (semaglutide) prescribing information, section 12.3: elimination half-life of about 1 week · Novo Nordisk, FDA-approved label
  2. Zepbound® (tirzepatide) prescribing information, section 12.3: half-life of about 5 days · Eli Lilly and Company, FDA-approved label
  3. Jastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (half-life of about 6 days) · New England Journal of Medicine, 2023

Wegovy®, Ozempic®, and Rybelsus® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company.